[{"orgOrder":0,"company":"Research Insight LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Research Insight LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral","sponsorNew":"Research Insight LLC \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Research Insight LLC \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prism Vision Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Prism Vision Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Prism Vision Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Prism Vision Group \/ Inapplicable"},{"orgOrder":0,"company":"Duke University","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Duke University \/ Ocular Therapeutix","highestDevelopmentStatusID":"9","companyTruncated":"Duke University \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Blephamide S.O.P.

Blephamide S.O.P.
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Blephamide S.O.P.

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 8 USDMF, 6 CEP/COS, 3 JDMF, 9 EU WC, 6 KDMF, 10 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

63 FDF Dossiers, 39 FDA Orange Book, 3 Europe, 7 Canada, 2 South Africa, 12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SUSPENSION;OPHTHALMIC - 0.2%;10%, SUSPENSION/DROPS;OPHTHALMIC - 1%, SUSPENSION/DROPS;OPHTHALMIC - 0.12%, SUSPENSION/DROPS;OPHTHALMIC - 1%, SUSPENSION/DROPS;OPHTHALMIC - EQ 0.3% BASE;1%, OINTMENT;OPHTHALMIC - EQ 0.3% BASE;0.6%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 5 DKSH, 1 Pharm-RX Chemical, 1 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 10 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 BASF, 1 Bioplus Life Sciences, 1 CD Formulation, 10 Corel Pharma Chem, 3 Finar, 8 Gangwal Chemicals, 4 Ideal Cures, 11 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 1 Microlex e.U, 2 Nanjing Bold Chemical, 2 Novo Excipients, 2 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 12 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Coating Systems & Additives, 17 Solubilizers, 17 Parenteral, 14 Controlled & Modified Release, 13 Topical, 10 Film Formers & Plasticizers, 9 Thickeners and Stabilizers, 8 Emulsifying Agents, 6 API Stability Enhancers, 6 Fillers, Diluents & Binders, 5 Taste Masking, 5 Empty Capsules, 4 Direct Compression, 4 Rheology Modifiers, 4 Vegetarian Capsules, 3 Granulation, 2 Surfactant & Foaming Agents, 2 Coloring Agents, 2 Lubricants & Glidants, 2 Co-Processed Excipients, 2 Disintegrants & Superdisintegrants, 1 Chewable & Orodispersible Aids

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 11 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 5 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

20 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents, 1 US Exclusivities

REF. STANDARDS & IMPURITIES

3 EDQM, 1 JP

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Mirvetuximab Soravtansine,Macrogol,Prednisolone Acetate

Therapeutic Area : Oncology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Partic...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

April 15, 2024

Lead Product(s) : Mirvetuximab Soravtansine,Macrogol,Prednisolone Acetate

Therapeutic Area : Oncology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Cyclosporine,Prednisolone Acetate

Therapeutic Area : Ophthalmology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acet...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Peptide

Upfront Cash : Inapplicable

May 10, 2010

Lead Product(s) : Cyclosporine,Prednisolone Acetate

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Amneal Pharmaceuticals

U.S.A

EPSC

Not Confirmed

04

Lupin Ltd

India

EPSC

Not Confirmed

05

Lupin Ltd

India

EPSC

Not Confirmed

06

Duke University

Country

EPSC

Not Confirmed

07

Prism Vision Group

Country

EPSC

Not Confirmed

08

Research Insight LLC

Country

EPSC

Not Confirmed

09

Carolina Eyecare Physicians, LLC

Country

EPSC

Not Confirmed

10

Carolina Eyecare Physicians, LLC

Country

EPSC

Not Confirmed

1
2